Eiger BioPharmaceuticals (EIGR) Doses First Patient in Ubenimex Phase 2 as Secondary Lymphedema Treatment
Tweet Send to a Friend
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced that the first patient in the Phase 2 ULTRA study was dosed at Stanford ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
